Urinary Incontinence and Overactive Bladder Syndrome in Women and Men: A Comprehensive Review of Pathophysiology, Diagnosis, and Contemporary Management

Abstract

Urinary incontinence (UI) and overactive bladder syndrome (OAB) represent significant public health burdens affecting millions of individuals worldwide. While these conditions have traditionally been viewed predominantly through the lens of female pelvic medicine, contemporary evidence underscores their substantial impact on male populations as well. This article provides a comprehensive, gender-specific analysis of the epidemiology, pathophysiology, diagnostic evaluation, and evidence-based management of urinary incontinence and overactive bladder syndrome in women and men, drawing upon established clinical guidelines and recent therapeutic advances.

1. Introduction

The involuntary loss of urine constitutes one of the most prevalent yet underreported chronic conditions in clinical practice. According to the International Continence Society (ICS), urinary incontinence falls into two broad categories: stress incontinence, characterized by leakage related to increases in intra-abdominal pressure, and urge incontinence, defined as leakage associated with an insuppressible desire to void. Overactive bladder syndrome, a closely related entity, is defined as urinary urgency, with or without urge incontinence, usually accompanied by frequency and nocturia. These conditions profoundly impair quality of life, restrict social participation, and impose substantial economic burdens on healthcare systems.

2. Urinary Incontinence and Overactive Bladder in Women

2.1 Epidemiology

Urinary incontinence is an extraordinarily common problem in women. Over one-third of women in the United States experience some degree of urinary incontinence, with an estimated annual cost of $19.5 billion. Overactive bladder alone affects approximately 17% of all women and 20% to 30% of women older than 55 years; the prevalence is even higher among nursing home residents. Remarkably, overactive bladder ranks as the third most prevalent chronic condition in the United States, following arthritis and sinusitis, with an estimated annual cost of $12.6 billion.

Despite these staggering figures, many patients fail to report bladder problems to their physicians, often due to the misconception that no effective treatments are available. Two-thirds of patients with urinary incontinence report that their bladder symptoms significantly affect daily living activities, leading many to self-manage through frequent voiding, fluid restriction, and absorbent pad use.

2.2 Anatomy and Physiology of the Female Lower Urinary Tract

The bladder functions as a smooth muscular reservoir (the detrusor muscle) with two inlets (ureters) and a single outlet (the urethra). Bladder function encompasses two distinct phases: storage and emptying. During storage, the detrusor muscle remains relaxed while urethral muscle tone increases under sympathetic and voluntary control. The emptying phase involves relaxation of urethral muscles and detrusor contraction, mediated primarily by the parasympathetic nervous system.

In women, the bladder and urethra are supported by the anterior vaginal wall, which is suspended by connective tissue attachments from the pelvic floor muscles, specifically the levator ani and internal obturator muscles. Continence is maintained when urethral closure pressure exceeds detrusor pressure. This relationship is critically dependent on anterior vaginal wall support during periods of increased intra-abdominal pressure. Consequently, urinary continence depends on the coordinated interaction of detrusor relaxation, urethral muscle contraction, and adequate anterior vaginal wall support.

2.3 Pathophysiology

Stress urinary incontinence (SUI) results from a decrease in urethral muscle capability or loss of vaginal wall support, leading to failure of the urethral closure mechanism during Valsalva maneuvers.

Urge urinary incontinence (UUI) typically occurs when the detrusor contracts inappropriately, either overcoming urethral pressure or triggering reflex relaxation of urethral muscles. The overactive bladder syndrome represents a broader clinical spectrum where inappropriate detrusor contractions may or may not overcome urethral closure pressure; in the latter instance, the patient maintains continence (so-called "dry" overactive bladder).

Other structural irregularities, including urinary tract fistulas, urethral obstruction, loss of detrusor contractility, anatomic tract anomalies, and ectopically located ureters, can also cause inappropriate urine leakage. Additionally, lower urinary tract infections, medications, pelvic masses, and systemic conditions may precipitate or exacerbate overactive bladder symptoms.

2.4 Diagnostic Evaluation

2.4.1 Clinical History

A comprehensive history should elicit conditions that may cause or contribute to urinary incontinence, including prior surgery to the spinal cord, bladder neck, or pelvic floor; neurologic disease (e.g., multiple sclerosis, spinal cord lesions); and psychiatric conditions (e.g., dementia). Musculoskeletal function, with emphasis on mobility, should be assessed. A detailed medication history identifies agents such as diuretics or alpha-blockers that may affect urine output or bladder function.

Daily fluid intake (40 to 60 ounces is considered normal) and voiding frequency should be documented. Four to eight voiding episodes per day is considered normal. Symptoms of dysuria raise concern for bladder infection or painful bladder syndrome. Gross hematuria warrants investigation for serious bladder pathology, including neoplasia.

The clinical diagnosis is facilitated by asking about the dominant symptom:

·        Leakage preceded by an urge to void suggests overactive bladder syndrome; persistence of leakage during the urge indicates urge incontinence.

·        Leakage exclusively with Valsalva activity (coughing, laughing, lifting) points to stress incontinence.

·        Pain associated with bladder fullness or emptying suggests painful bladder syndrome.

·        Bothersome nocturia may indicate obstructive sleep apnea or cardiovascular disease.

·        Continuous urine leakage suggests urinary-vaginal fistula.

2.4.2 Physical Examination

The examination should evaluate mental status, general appearance, and mobility. In the absence of cystitis, a targeted examination focuses on inspection and palpation of the back, abdomen, urethra, bladder, vagina, uterus, and adnexa to exclude gross masses, pelvic organ prolapse, and urethral diverticula. Inspection of the lower back may reveal anatomic anomalies (e.g., spina bifida) or spinal surgery scars.

A speculum examination evaluates for atrophic vaginitis, which can be associated with overactive bladder symptoms in postmenopausal women. Prolapse of the vagina or cervix beyond the labia indicates advanced prolapse, sometimes associated with urinary retention and frequency. Transvaginal palpation of pelvic floor muscles may elicit tenderness of trigger points, suggesting pelvic myofascial dysfunction.

A focused neurologic examination includes perineal sensation, the anal wink reflex, patellar reflexes, and lower extremity motor function. The supine cough stress test (CST) is performed with the patient in the lithotomy position; immediate urine leakage from the urethral meatus with coughing confirms stress urinary incontinence.

2.4.3 Bladder Diary and Laboratory Testing

When the type of incontinence remains unclear, a bladder diary can quantify voiding frequency, volume, and fluid intake patterns. Maximum voided volumes exceeding 300 mL suggest adequate bladder capacity. Urinalysis is essential to exclude cystitis. Postvoid residual urine measurement (normal: <100 mL) identifies voiding dysfunction requiring further evaluation.

2.4.4 Urodynamic Testing

Advanced bladder testing is generally unnecessary when noninvasive therapy is planned. However, when noninvasive therapy fails or invasive intervention is desired, urodynamic testing is recommended to confirm the diagnosis and exclude associated pathologies. Some specialists consider urodynamic testing optional in clear cases of uncomplicated stress incontinence meeting specific criteria: symptoms consistent with stress incontinence, positive cough stress test, no voiding dysfunction, no prior bladder neck surgery, no advanced prolapse, and no comorbid conditions affecting bladder function.

2.5 Management

2.5.1 Stress Urinary Incontinence

Conservative Management

·        Pelvic Floor Muscle Exercises (PFME): Intensive pelvic floor muscle exercise therapy can yield cure rates of up to 25% at 5 years with diligent practice. The patient contracts pelvic floor muscles for 10 repetitions per cycle, holding each contraction for up to 5 seconds with 3-second rest intervals, repeated up to three times daily. Preemptive contraction before coughing, laughing, sneezing, or lifting is encouraged.

·        Incontinence Pessaries: Flexible vaginal inserts that compress the bladder neck during Valsalva maneuvers. Pessaries cure stress incontinence in up to 24% of women. While two-thirds of patients will try a pessary, up to 45% discontinue use within 6 months. Pessaries should be removed at least every 3 months for cleaning and vaginal inspection.

·        Pharmacologic Therapy: Currently, no FDA-approved pharmacologic therapy exists for stress urinary incontinence. Prior investigation into norepinephrine-serotonin reuptake inhibitors was discontinued due to concerns about mental health risks.

Surgical Therapy

When conservative therapy fails, urodynamic confirmation is advised. Surgical options include:

·        Periurethral Bulking Agents: Injected under cystoscopic guidance; success rates of 16% to 22% at 3 months and 6% to 18% at 1 year. Repeat injections are often required.

·        Retropubic Urethropexy (Burch Procedure): Long-term success rates of approximately 82%, but requires general or regional anesthesia and suprapubic incision.

·        Suburethral Slings: Long-term success rates of approximately 85%. Synthetic midurethral slings (e.g., Tension-Free Vaginal Tape, TVT) demonstrate approximately 80% success at 2 years, with a 22% complication rate including retropubic hematomas (2%), bladder perforation (9%), postoperative urinary retention (11%), and vaginal wall erosion (2.4%). The TVT procedure requires less than 30 minutes, can be performed under various anesthesia options, and over 95% of patients are discharged on the same day without a catheter.

2.5.2 Urinary Frequency and Urge Incontinence (Overactive Bladder)

Pharmacologic Treatment

Antimuscarinic agents remain the mainstay of therapy, antagonizing M2 and M3 receptors in the bladder wall to reduce detrusor irritability. Currently approved agents include oxybutynin, tolterodine, trospium, oxybutynin transdermal patch, solifenacin, and darifenacin. These agents appear equally effective but vary in side effect profiles, including dry mouth, constipation, somnolence, and ECG changes. Antimuscarinics are contraindicated in uncontrolled narrow-angle glaucoma.

A stepwise pharmacologic approach begins with generic oxybutynin 2.5 mg twice daily, titrating to 5 mg twice daily and then 10 mg twice daily if needed. For patients preferring once-daily dosing, tolterodine 2 mg at bedtime (titratable to 4 mg) is appropriate. Side effects can be managed with hard candies for dry mouth and stool softeners for constipation. Mental status changes in elderly patients require careful monitoring.

Non-Pharmacologic Therapies

·        Bladder Retraining: Attempts to recalibrate the central response to bladder filling by gradually increasing voiding intervals. Beginning with the minimum voiding interval from the diary, the interval is increased by 15 to 30 minutes every 2 weeks until 2.5 to 3 hours is achieved. Clinical trials demonstrate cure rates of 55% to 60% at 12 weeks.

·        Pelvic Floor Muscle Exercises: Based on the theory that tightly held pelvic floor muscles produce a sensation of bladder fullness interpreted as urgency. Daily exercises have decreased incontinence episodes by up to 82% in some studies.

·        Pelvic Floor Physical Therapy: Weekly sessions of transvaginal manual myofascial release targeting levator ani tightness and trigger points. Studies demonstrate moderate to marked improvement in 35 of 42 patients with urinary urgency and frequency.

·        Vaginal Electrical Stimulation: Transvaginal stimulation of the pudendal nerve inhibits parasympathetic outflow to the detrusor. Eight weeks of therapy cures overactive bladder in 40% to 50% of patients and has Medicare approval for this indication.

Advanced Therapy for Refractory Overactive Bladder

When conservative therapies fail, referral to a pelvic floor specialist is indicated. Options include:

·        Sacral Neuromodulation: A two-stage procedure involving placement of an electrical lead into the S3 sacral foramen. In prospective trials, neuromodulation completely cured 46% of patients with refractory leakage and eliminated heavy leakage in 65% at 3 years. Complications include lead migration (11.8%), pain (2.1%), and technical problems (2.6%).

·        Intradetrusor Botulinum Toxin A: Up to 300 units injected into the supratrigonal detrusor muscle under cystoscopic guidance. Complete continence was achieved in 72% of patients with neurogenic detrusor overactivity, with effects persisting at 9 months. All patients must be taught self-catheterization due to the risk of urinary retention.

3. Urinary Incontinence and Overactive Bladder in Men

3.1 Epidemiology and Gender-Specific Considerations

While urinary incontinence has historically been perceived as predominantly a female condition, male urinary incontinence represents a significant and growing clinical concern. The epidemiology in men differs substantially from women, with post-prostatectomy stress urinary incontinence (PPI-SUI) constituting the most common etiology in younger and middle-aged men. Following radical prostatectomy, the prevalence of stress urinary incontinence ranges widely depending on surgical technique, surgeon experience, and definition criteria, with reported rates between 1% and 40%.

In older men, overactive bladder symptoms frequently coexist with benign prostatic obstruction (BPO), creating a complex clinical picture where storage and voiding symptoms overlap. The prevalence of overactive bladder in men increases with age, paralleling the rise in benign prostatic hyperplasia (BPH), though the two conditions are pathophysiologically distinct.

3.2 Pathophysiology in Men

The male lower urinary tract is anatomically distinct, with the prostate gland surrounding the proximal urethra. This anatomical relationship means that any prostatic pathology—whether inflammatory, hyperplastic, or neoplastic—directly impacts urethral resistance and bladder function.

Post-Prostatectomy Stress Urinary Incontinence: Results primarily from damage to the external urethral sphincter mechanism during radical prostatectomy. The sphincter complex, comprising intrinsic smooth muscle and extrinsic striated muscle components, may be compromised by surgical dissection, leading to intrinsic sphincter deficiency. Additionally, nerve injury during pelvic surgery can impair sphincter innervation.

Overactive Bladder in Men: May arise from primary detrusor overactivity (idiopathic or neurogenic) or secondary to bladder outlet obstruction (BOO) from BPH. The latter represents a form of "compensated" bladder dysfunction where the detrusor muscle hypertrophies and becomes unstable in response to increased outflow resistance. Chronic obstruction can ultimately lead to detrusor decompensation and underactive bladder.

Underactive Bladder (UAB): An increasingly recognized condition in men, particularly elderly populations, characterized by reduced detrusor contractility leading to incomplete bladder emptying, elevated postvoid residual volumes, and sometimes overflow incontinence.

3.3 Diagnostic Evaluation in Men

3.3.1 History and Physical Examination

The evaluation of male urinary incontinence requires a comprehensive history including prior prostate surgery, radiation therapy, neurologic disease, and medication use. Validated symptom score questionnaires (e.g., International Prostate Symptom Score) and bladder diaries assist in categorizing symptoms. A pad test quantifies the severity of incontinence and treatment response.

Physical examination focuses on the abdomen, external genitalia, and digital rectal examination to assess prostate size, consistency, and pelvic floor muscle tone. Neurologic examination of the perineum and lower extremities is essential.

3.3.2 Urodynamic Assessment

Urodynamic testing plays a more prominent role in male incontinence evaluation than in uncomplicated female stress incontinence. In a retrospective evaluation of 668 urodynamic studies in men with urgency symptoms, detrusor overactivity was documented in 38.6% and bladder outlet obstruction in 43.9%. Urodynamics should be considered when invasive treatment is contemplated, particularly to distinguish stress incontinence from detrusor overactivity and to evaluate bladder outlet obstruction.

Urethrocystoscopy may be performed to exclude urethral or bladder neck strictures, particularly in patients with prior prostate surgery. Imaging (ultrasound, MRI, CT) can clarify anatomical abnormalities contributing to incontinence.

3.4 Management

3.4.1 Conservative and Behavioral Therapies

Pelvic Floor Muscle Training (PFMT): The cornerstone of conservative management, particularly for post-prostatectomy incontinence. PFMT should be initiated routinely after catheter removal following prostate surgery. Current evidence supports that PFMT supported by EMG biofeedback and electrostimulation provides the most effective outcomes. Multimodal therapy combining pelvic floor training, breathing exercises, and core stabilization accelerates recovery of sphincter function. For optimal recovery, at least 6 months of healing is recommended for severe incontinence and 12 months for mild to moderate cases before considering surgical intervention.

Bladder Training: Goals include correcting faulty habit patterns of frequent urination, improving control over bladder urgency, prolonging voiding intervals, and restoring patient confidence. While bladder training alone has shown limited benefit in men, it may be combined with antimuscarinic therapy for additive effects on frequency and nocturia.

Prompted or Timed Voiding: Particularly applicable for cognitively impaired individuals, with carers initiating the decision to void at fixed intervals.

Containment: Non-surgical management options including absorbent pads, penile compression devices, and collection products are offered during the recovery period.

3.4.2 Pharmacologic Management

For Urgency Urinary Incontinence/Overactive Bladder:

Antimuscarinic agents and β3-adrenoceptor agonists constitute first-line pharmacotherapy. In men with concomitant benign prostatic obstruction, combination therapy with α1-blockers and antimuscarinics or β3-agonists is effective for improving quality of life and reducing storage symptoms. However, combination therapy should not be prescribed in men with postvoid residual volumes exceeding 150 mL due to the risk of acute urinary retention.

Gemtesa® (Vibegron): The first and only β3-adrenergic receptor agonist approved (December 2024) for men with OAB symptoms receiving pharmacologic therapy for BPH, addressing a critical treatment gap for men with persistent OAB despite alpha-blocker or 5-ARI treatment.

For Stress Urinary Incontinence:

Duloxetine, though not officially approved for post-prostatectomy SUI and associated with notable side effects, has demonstrated dry rates of up to 58% and may be considered for select patients with mild to moderate symptoms who are aware of potential adverse effects and prefer to avoid surgery.

3.4.3 Surgical Management of Male Stress Urinary Incontinence

Surgical intervention is considered after 6 to 12 months of conservative management in patients significantly affected by their symptoms.

Male Synthetic Urethral Slings: Comparable to artificial urinary sphincters for mild to moderate PPI-SUI. Options include non-adjustable, adjustable, and autologous slings.

Artificial Urinary Sphincter (AUS): Considered the gold standard for moderate to severe PPI-SUI, particularly in patients with a history of radiotherapy. AUS implantation should only be offered in expert centers, with patients counseled about the high risk of complications, mechanical failure, and potential need for explantation.

Bulking Agents: Not typically recommended and only provided when no other surgical options are viable, given the limited likelihood of improvement.

Compression Devices: The ProACT® non-circumferential compression device offers a reasonable alternative but is contraindicated in patients with prior pelvic radiotherapy and is associated with high complication rates.

3.4.4 Surgical Management of Male Urgency Urinary Incontinence

Bladder Wall Injection of Botulinum Toxin-A: Effective for refractory detrusor overactivity, with urodynamic testing and voiding diaries demonstrating up to 58% reduction in leakage at 24 weeks after treatment.

Sacral Nerve Stimulation (Neuromodulation): Effective for refractory urgency urinary incontinence, with long-term outcomes demonstrating sustained benefit.

Cystoplasty/Urinary Diversion: Reserved as a last resort for complex or refractory cases.

3.5 Emerging Technologies and Future Directions

Recent advances have transformed the therapeutic landscape for male urinary dysfunction:

·        Battery-Free Sacral Neuromodulation: The Neuspera® iSNM System (FDA-approved June 2025) eliminates implanted batteries entirely, using a miniaturized neurostimulator paired with an external wireless disc worn approximately 2 hours daily. Clinical trials demonstrated an 84% responder rate and 42% complete dryness.

·        Integrated Tibial Neuromodulation: The ALTAVIVA™ and Revi® systems offer automatic or patient-controlled therapy, respectively, providing intermediate options between conservative therapy and sacral neuromodulation.

·        Extracorporeal Shock Wave Therapy (ESWT): Shows theoretical promise for improving detrusor contractility in underactive bladder through neovascularization and tissue regeneration, though long-term data remain limited.

4. Differential Diagnosis and Red Flags

In both women and men, the evaluation of urinary incontinence must exclude readily identifiable causes unrelated to primary detrusor or sphincter dysfunction. These include:

·        Cystitis/UTI: Common cause of bladder irritation with frequency, urgency, and sometimes incontinence.

·        Medications: Diuretics, alpha-blockers, and other agents affecting bladder function.

·        Diabetes Mellitus: Osmotic diuresis and autonomic neuropathy.

·        Neoplasia: Gross hematuria requires specialized workup.

·        Neurologic Disease: Multiple sclerosis, spinal cord injury, Parkinson's disease.

·        Obstructive Sleep Apnea and Congestive Heart Failure: May cause nocturia through distinct mechanisms.

·        Excessive Fluid Intake: Often overlooked; daily intake should be 40 to 60 ounces.

Most of these conditions can be eliminated through a thorough history and targeted physical examination.

5. Prognosis

Conservative therapy provides effective treatment in 50% to 80% of patients with overactive bladder syndrome. When noninvasive therapies fail, minimally invasive surgical options substantially improve symptoms in a large percentage of refractory cases. For stress urinary incontinence, conservative therapies are less effective, but minimally invasive surgical therapies demonstrate excellent outcomes. The short operating times and minimal long-term sequelae associated with modern surgical approaches make them well-suited for elderly patients and those with significant comorbidities.

6. Conclusion

Urinary incontinence and overactive bladder syndrome represent complex, multifactorial conditions that affect both women and men, albeit with distinct epidemiologic profiles, pathophysiologic mechanisms, and therapeutic considerations. In women, the spectrum ranges from stress incontinence related to pelvic floor support defects to urge incontinence from detrusor overactivity, with a robust evidence base supporting pelvic floor rehabilitation, pharmacotherapy, and minimally invasive surgical interventions. In men, the clinical picture is heavily influenced by prostatic pathology and its surgical treatment, necessitating a tailored approach that addresses both storage and voiding dysfunction. Contemporary management emphasizes shared decision-making, personalized treatment selection, and the integration of advanced neuromodulation technologies. As our understanding of lower urinary tract pathophysiology continues to evolve, so too will our capacity to deliver effective, patient-centered care for these prevalent and impactful conditions.

References

1.     Hannestad YS, Rortveit G, Sandvik H, et al. A community-based epidemiological survey of female urinary incontinence: the Norwegian Epincont study. J Clin Epidemiol. 2000;53:1150.

2.     Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21:167.

3.     Hu TW, Wagner TH, Bentkover JD, et al. Costs of urinary incontinence and overactive bladder in the United States: a comparative study. Urology. 2004;63:461.

4.     Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20:327.

5.     De Groat W. Anatomy and physiology of the lower urinary tract. Urol Clin North Am. 1993;20:383.

6.     De Groat WC. A neurologic basis for the overactive bladder. Urology. 1997;50:36.

7.     European Association of Urology. Guidelines on Management of Non-Neurogenic Male LUTS. 2024.

8.     American Urological Association/Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction. Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline. 2024.

9.     Heesakkers JPFA, et al. Two-year efficacy and safety outcomes of the pivotal OASIS trial using the Revi® system for treatment of urgency urinary incontinence. J Urol. 2025;213(3):323-332.

10.  Sumitomo Pharma America, Inc. U.S. FDA approves GEMTESA® (vibegron) for men with overactive bladder symptoms receiving pharmacological therapy for benign prostatic hyperplasia. December 2024.